Resveratrol improves myocardial ischemia and ischemic heart failure in mice by antagonizing the detrimental effects of fractalkine

Critical Care Medicine

Volumn 40, Issue 11, 2012, Pages 3026-3033

  Xuan, Wanling ^a   Wu, Bing ^a   Chen, Ci ^a   Chen, Baihe ^a   Zhang, Wenqing ^b   Xu, Dingli ^a   Bin, Jianping ^a,b   Liao, Yulin ^a,b  

^a FIRST MILITARY MEDICAL UNIVERSITY   (China)

^b SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

autophagy; cardiac remodeling; fractalkine; heart failure; myocardial ischemia; resveratrol

Indexed keywords

ATRIAL NATRIURETIC FACTOR; FRACTALKINE; GELATINASE B; HYDROGEN PEROXIDE; INTERCELLULAR ADHESION MOLECULE 1; PROCOLLAGEN; RESVERATROL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOPHAGY; BODY WEIGHT; CELL HYPOXIA; CONTROLLED STUDY; CORONARY ARTERY LIGATION; DISEASE COURSE; ECHOCARDIOGRAPHY; HEART CELL CULTURE; HEART FAILURE; HEART INFARCTION SIZE; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HEART WEIGHT; LUNG WEIGHT; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REOXYGENATION; SURVIVAL RATE;

ANIMALS; ANIMALS, NEWBORN; CHEMOKINE CX3CL1; DISEASE MODELS, ANIMAL; ELECTROCARDIOGRAPHY; HEART FAILURE; MALE; MICE; MICE, INBRED C57BL; MYOCARDIAL ISCHEMIA; PLATELET AGGREGATION INHIBITORS; RANDOM ALLOCATION; RATS; STILBENES; VENTRICULAR REMODELING;

EID: 84868197080     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e31825fd7da     Document Type: Article

References (34)

1. Burstein B, Maguy A, Cl?ent R, et al: Effects of resveratrol (trans-3,5,4'-trihydroxystilbene) treatment on cardiac remodeling following myocardial infarction. J Pharmacol Exp Ther 2007; 323:916-923
2. Dolinsky VW, Chan AY, Robillard Frayne I, et al: Resveratrol prevents the prohypertrophic effects of oxidative stress on LKB1. Circulation 2009; 119:1643-1652
3. Opie LH, Lecour S: The red wine hypothesis: From concepts to protective signalling molecules. Eur Heart J 2007; 28:1683-1693
4. Robich MP, Osipov RM, Nezafat R, et al: Resveratrol improves myocardial perfusion in a swine model of hypercholesterolemia and chronic myocardial ischemia. Circulation 2010; 122(11 Suppl):S142-S149
5. Petrovski G, Gurusamy N, Das DK: Resveratrol in cardiovascular health and disease. Ann N Y Acad Sci 2011; 1215:22-33
6. Wu JM, Hsieh TC: Resveratrol: A cardioprotective substance. Ann N Y Acad Sci 2011; 1215:16-21
7. Ungvari Z, Labinskyy N, Mukhopadhyay P, et al: Resveratrol attenuates mitochondrial oxidative stress in coronary arterial endothelial cells. Am J Physiol Heart Circ Physiol 2009; 297:H1876-H1881
8. Alcendor RR, Gao S, Zhai P, et al: Sirt1 regulates aging and resistance to oxidative stress in the heart. Circ Res 2007; 100:1512-1521
9. Baur JA, Pearson KJ, Price NL, et al: Resveratrol improves health and survival of mice on a high-calorie diet. Nature 2006; 444:337-342
10. Husberg C, Nygd S, Finsen AV, et al: Cytokine expression profiling of the myocardium reveals a role for CX3CL1 (fractalkine) in heart failure. J Mol Cell Cardiol 2008; 45:261-269
11. Escher F, Vetter R, K?l U, et al: Fractalkine in human inflammatory cardiomyopathy. Heart 2011; 97:733-739
12. Inoue A, Hasegawa H, Kohno M, et al: Antagonist of fractalkine (CX3CL1) delays the initiation and ameliorates the progression of lupus nephritis in MRL/lpr mice. Arthritis Rheum 2005; 52:1522-1533
13. Liu H, Jiang D, Zhang S, et al: Aspirin inhibits fractalkine expression in atherosclerotic plaques and reduces atherosclerosis in ApoE gene knockout mice. Cardiovasc Drugs Ther 2010; 24:17-24
14. Xuan W, Liao Y, Chen B, et al: Detrimental effect of fractalkine on myocardial ischaemia and heart failure. Cardiovasc Res 2011; 92:385-393
15. Moon SO, Kim W, Sung MJ, et al: Resveratrol suppresses tumor necrosis factor-alphainduced fractalkine expression in endothelial cells. Mol Pharmacol 2006; 70:112-119
16. Gustafsson AB, Gottlieb RA: Autophagy in ischemic heart disease. Circ Res 2009; 104:150-158
17. Nishida K, Yamaguchi O, Otsu K: Crosstalk between autophagy and apoptosis in heart disease. Circ Res 2008; 103:343-351
18. Koyama T, Temma K, Akera T: Reperfusioninduced contracture develops with a decreasing [Ca2+]i in single heart cells. Am J Physiol 1991; 261(4 Pt 2):H1115-H1122
19. Krishnamurthy P, Subramanian V, Singh M, et al: Deficiency of beta1 integrins results in increased myocardial dysfunction after myocardial infarction. Heart 2006; 92:1309-1315
20. Liao Y, Ishikura F, Beppu S, et al: Echocardiographic assessment of LV hypertrophy and function in aortic-banded mice: Necropsy validation. Am J Physiol Heart Circ Physiol 2002; 282:H1703-H1708
21. Liao Y, Zhao H, Ogai A, et al: Atorvastatin slows the progression of cardiac remodeling in mice with pressure overload and inhibits epidermal growth factor receptor activation. Hypertens Res 2008; 31:335-344
22. Ferrera R, Benhabbouche S, Bopassa JC, et al: One hour reperfusion is enough to assess function and infarct size with TTC staining in Langendorff rat model. Cardiovasc Drugs Ther 2009; 23:327-331
23. Liao Y, Xuan W, Zhao J, et al: Antihypertrophic effects of adiponectin on cardiomyocytes are associated with the inhibition of heparin-binding epidermal growth factor signaling. Biochem Biophys Res Commun 2010; 393:519-525
24. Consolo M, Amoroso A, Spandidos DA, et al: Matrix metalloproteinases and their inhibitors as markers of inflammation and fibrosis in chronic liver disease (Review). Int J Mol Med 2009; 24:143-152
25. Moshal KS, Rodriguez WE, Sen U, et al: Targeted deletion of MMP-9 attenuates myocardial contractile dysfunction in heart failure. Physiol Res 2008; 57:379-384
26. Frangogiannis NG, Smith CW, Entman ML: The inflammatory response in myocardial infarction. Cardiovasc Res 2002; 53:31-47
27. Lawson C, Wolf S: ICAM-1 signaling in endothelial cells. Pharmacol Rep 2009; 61:22-32
28. Yang XP, Irani K, Mattagajasingh S, et al: Signal transducer and activator of transcription 3alpha and specificity protein 1 interact to upregulate intercellular adhesion molecule-1 in ischemic-reperfused myocardium and vascular endothelium. Arterioscler Thromb Vasc Biol 2005; 25:1395-1400
29. Schulz C, Sch?er A, Stolla M, et al: Chemokine fractalkine mediates leukocyte recruitment to inflammatory endothelial cells in flowing whole blood: A critical role for P-selectin expressed on activated platelets. Circulation 2007; 116:764-773
30. Liu Y, Gao XM, Fang L, et al: Novel role of platelets in mediating inflammatory responses and ventricular rupture or remodeling following myocardial infarction. Arterioscler Thromb Vasc Biol 2011; 31: 834-841
31. Dong F, Khalil M, Kiedrowski M, et al: Critical role for leukocyte hypoxia inducible factor-1alpha expression in post-myocardial infarction left ventricular remodeling. Circ Res 2010; 106:601-610
32. Korhonen T, H?ninen SL, Tavi P: Model of excitation-contraction coupling of rat neonatal ventricular myocytes. Biophys J 2009; 96:1189-1209
33. Tiede K, Melchior-Becker A, Fischer JW: Transcriptional and posttranscriptional regulators of biglycan in cardiac fibroblasts. Basic Res Cardiol 2010; 105:99-108
34. Mountain DJ, Singh M, Menon B, et al: Interleukin-1beta increases expression and activity of matrix metalloproteinase-2 in cardiac microvascular endothelial cells: Role of PKCalpha/beta1 and MAPKs. Am J Physiol Cell Physiol 2007; 292:C867-C875